Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis

  • Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented
  • Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral session
/by

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis

  • Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented
  • Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral session
/by

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis

  • Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented
  • Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral session
/by